'Permissive' USPTO Patent Policies Raise Drug Prices: Study
The high cost of prescription drugs in the U.S. is connected to the U.S. Patent and Trademark Office's "permissive" practices of granting branded drugmakers new patents on nontherapeutic aspects of drugs,...To view the full article, register now.
Already a subscriber? Click here to view full article